Ernexa Therapeutics Inc. (ERNA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | - | - | 487 | 47 |
| Cost of revenues | - | - | -60 | 95 |
| Gross loss | - | - | 547 | -48 |
| Gain (loss) on termination of lease | - | - | 1,576 | - |
| Research and development | 1,136 | 1,309 | 1,001 | 987 |
| General and administrative | 1,365 | 1,421 | 3,381 | 3,896 |
| Total operating expenses | 2,501 | 2,730 | 2,806 | 4,883 |
| Loss from operations | -2,501 | -2,730 | -2,259 | -4,931 |
| Loss on extinguishment of debt | - | - | -22,440 | - |
| Fair value adjustments to bridge notes derivative liability | - | - | -1,038 | - |
| Other expense, net | -123 | -135 | - | - |
| Interest (expense) income, net | - | 5 | -1,686 | -797 |
| Change in fair value of warrant liabilities | - | -1 | -831 | -136 |
| Forward sales contract expense | -512 | -5,335 | - | - |
| Change in fair value of contingent consideration | - | - | - | 66 |
| Total other expense, net | -635 | -5,464 | -24,333 | -595 |
| Loss before income taxes | -3,136 | -8,194 | -26,592 | -5,526 |
| Provision for income taxes | 3 | 8 | 12 | 3 |
| Net loss | -3,139 | -8,202 | -26,604 | -5,529 |
| Series a preferred stock dividend | 8 | - | - | 8 |
| Net loss attributable to common stockholders | -3,147 | -8,202 | -26,604 | -5,537 |
| Net loss per common share - basic | -0.61 | -0.15 | -4.92 | -1.02 |
| Net loss per common share - diluted | -0.61 | -0.15 | -4.92 | -1.02 |
| Weighted average shares outstanding - basic | 5,179,000 | 53,361,000 | 5,410,000 | 5,410,000 |
| Weighted average shares outstanding - diluted | 5,179,000 | 53,361,000 | 5,410,000 | 5,410,000 |